Title
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Code
A5481092
Type
Sperimentale con farmaco
Start Year
2023
Status
In progress
Principal Investigator
051-6366101
emanuela.palmerini@ior.it
Operational unit that carry out the study
complex unit
Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative
Director
:Documents and Videos attachament
Attachment
PG0011444_2023_studio clinico.pdf